Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Takao Ohtsuka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2946-1092; OpenAlex author ID A5085781479. Sources: OpenAlex.

Their work

Papers
94 (first author 16, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
147
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 11 papers · 2014: 7 papers · 2015: 4 papers · 2016: 6 papers · 2017: 8 papers · 2018: 5 papers · 2019: 6 papers · 2020: 9 papers · 2021: 9 papers · 2022: 3 papers · 2023: 6 papers · 2024: 2 papers · 2025: 4 papers · 2026: 8 papers

Papers 50 of 94

  1. Pancreatic cancer: An urgent clinical challenge and opportunities for improved care. Last author DOI 10.1016/j.pan.2025.11.009↗
  2. Positioning serum autoantibody signatures within the evolving landscape of early pancreatic cancer detection. Last author DOI 10.1016/j.pan.2025.12.016↗
  3. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  4. Leveraging population-based health checkup data for pancreatic cancer risk stratification: toward pragmatic early detection Last author DOI 10.1016/j.pan.2026.04.014↗
  5. From diagnostic technology to pathway design: what the Onomichi Method teaches us about early pancreatic cancer detection. Last author DOI 10.1016/j.pan.2026.04.021↗
  6. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  7. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  8. Aldehyde Dehydrogenase 2 Activity Assessed Using the Acetaldehyde Breath Test Is Associated with Benign Pancreatic Disease and Pancreatic Cancer: A Case-Contro… Co-author DOI 10.3390/jcm15197543↗
  9. Efficacy and Safety of Surgical Treatment Among Older Adult Patients (80 Years) With Pancreatic Cancer: A Systematic Review and Meta-Analysis. First author DOI 10.1002/jhbp.12151↗
  10. Defining oligo-recurrence criteria for locoregional intervention in pancreatic ductal adenocarcinoma: A multidisciplinary era perspective. Co-author DOI 10.1016/j.pan.2025.08.020↗
  11. Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17792↗
  12. Strategies to Target the Tumor-Associated Macrophages in the Immunosuppressive Microenvironment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers17183090↗
  13. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/deo2.333↗
  14. Genetic Assessment of Intraductal Papillary Mucinous Neoplasm for Predicting Concomitant Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002373↗
  15. Efficacy and safety of a novel anti-reflux metal stent during neoadjuvant chemotherapy for pancreatic cancer: A prospective multicenter exploratory study. Co-author DOI 10.1002/jhbp.1239↗
  16. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  17. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  18. ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement. Co-author DOI 10.1245/s10434-022-12584-z↗
  19. Next-Generation Sequencing Analysis of Pancreatic Cancer Using Residual Liquid Cytology Specimens from Endoscopic Ultrasound-Guided Fine-Needle Biopsy: A Prosp… Co-author DOI 10.3390/diagnostics13061078↗
  20. Coronin 1C, Regulated by Multiple microRNAs, Facilitates Cancer Cell Aggressiveness in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/genes14050995↗
  21. Sequential evaluation of MUC promoter methylation using next-generation sequencing-based custom-made panels in liquid-based cytology specimens of pancreatic ca… Co-author DOI 10.1002/dc.25022↗
  22. Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compa… Co-author DOI 10.1007/s00423-022-02453-4↗
  23. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis. Last author DOI 10.21873/anticanres.15824↗
  24. Minimally invasive surgery for pancreatic cancer. First author DOI 10.1007/s00595-020-02120-5↗
  25. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. First author DOI 10.1007/s00595-020-02123-2↗
  26. Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrine neoplasm type 1. Co-author DOI 10.1007/s12328-020-01234-0↗
  27. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2021.04.013↗
  28. The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer. Co-author DOI 10.1111/cas.14858↗
  29. Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy. Last author DOI 10.1245/s10434-021-09712-6↗
  30. Impact of Oncogenic Targets Controlled by Tumor-Suppressive miR-30a-5p in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.15297↗
  31. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Mult… First author DOI 10.29337/ijsp.142↗
  32. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Last author DOI 10.3390/cancers13051057↗
  33. Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer? First author DOI 10.1002/ags3.12340↗
  34. High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neo… First author DOI 10.1007/s00595-019-01852-3↗
  35. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in… Co-author DOI 10.1097/sla.0000000000003060↗
  36. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  37. Molecular Pathogenesis of Pancreatic Ductal Adenocarcinoma: Impact of miR-30c-5p and miR-30c-2-3p Regulation on Oncogenic Genes. Co-author DOI 10.3390/cancers12102731↗
  38. Early Detection of Pancreatic Cancer: Role of Biomarkers in Pancreatic Fluid Samples. Last author DOI 10.3390/diagnostics10121056↗
  39. Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis. Co-author DOI 10.3390/ijms21186459↗
  40. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Co-author DOI 10.3892/ijo.2019.4951↗
  41. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Co-author DOI 10.7150/thno.47001↗
  42. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  43. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Co-author DOI 10.1007/s00432-019-02860-z↗
  44. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  45. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07269-z↗
  46. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. First author DOI 10.1245/s10434-019-07309-8↗
  47. S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. Co-author DOI 10.3892/ijo.2019.4812↗
  48. Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. Co-author DOI 10.1016/j.canlet.2017.10.010↗
  49. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2018.03.031↗
  50. Multicenter study of early pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2017.11.007↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Nakamura · 38 shared papers, 2012–2026 · strength 3.21
  2. Yoshihiro Miyasaka · 34 shared papers, 2015–2025 · strength 3.04
  3. Kenoki Ohuchida · 45 shared papers, 2011–2026 · strength 2.85
  4. Kohei Nakata · 25 shared papers, 2017–2026 · strength 2.56
  5. Yoshinao Oda · 32 shared papers, 2013–2025 · strength 2.26
  6. Naoki Ikenaga · 15 shared papers, 2012–2026 · strength 2.02
  7. Masafumi Nakamura · 15 shared papers, 2016–2025 · strength 1.82
  8. Tetsuya Idichi · 10 shared papers, 2020–2026 · strength 1.62
  9. Yasuhisa Mori · 18 shared papers, 2013–2025 · strength 1.60
  10. Noboru Ideno · 15 shared papers, 2013–2026 · strength 1.54
  11. Masao Tanaka · 31 shared papers, 2011–2026 · strength 1.34
  12. Hiroshi Kurahara · 10 shared papers, 2019–2024 · strength 1.32
  13. Toshiya Abe · 15 shared papers, 2016–2026 · strength 1.29
  14. Yuko Mataki · 6 shared papers, 2021–2026 · strength 1.10
  15. Yuto Hozaka · 7 shared papers, 2020–2025 · strength 1.06
  16. Koji Shindo · 16 shared papers, 2012–2021 · strength 0.98
  17. Shinichi Hashimoto · 5 shared papers, 2022–2026 · strength 0.96
  18. Takashi Okumura · 14 shared papers, 2016–2021 · strength 0.92
  19. Keiji Hanada · 4 shared papers, 2018–2026 · strength 0.79
  20. Masayuki Kitano · 4 shared papers, 2018–2026 · strength 0.79
  21. Yasuhisa Mori · 2 shared papers, 2026 · strength 0.74
  22. Shin Takesue · 10 shared papers, 2017–2020 · strength 0.69
  23. Chika Iwamoto · 9 shared papers, 2017–2021 · strength 0.67
  24. Kazuhiro Koikawa · 10 shared papers, 2017–2021 · strength 0.65
  25. Yohei Ando · 8 shared papers, 2017–2021 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.